Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)
Provided By GlobeNewswire
Last update: Jul 14, 2025
July 14, 2025
Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in
Familial Adenomatous Polyposis (FAP)
Read more at globenewswire.comNASDAQ:BDRX (8/28/2025, 10:04:50 AM)
5.8
+0.09 (+1.58%)
Find more stocks in the Stock Screener
